Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cresco Labs (CRLBF) EBITDA (2020 - 2026)

Cresco Labs filings provide 7 years of EBITDA readings, the most recent being $11.2 million for Q1 2026.

  • On a quarterly basis, EBITDA fell 17.78% to $11.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$30.4 million, a 133.15% decrease, with the full-year FY2025 number at -$139.4 million, down 84.65% from a year prior.
  • EBITDA hit $11.2 million in Q1 2026 for Cresco Labs, up from -$75.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $32.4 million in Q2 2024 to a low of -$143.5 million in Q4 2022.
  • Median EBITDA over the past 5 years was $16.2 million (2022), compared with a mean of -$4.8 million.
  • Biggest five-year swings in EBITDA: crashed 1022.28% in 2022 and later skyrocketed 713.25% in 2024.
  • Cresco Labs' EBITDA stood at -$143.5 million in 2022, then skyrocketed by 118.89% to $27.1 million in 2023, then decreased by 28.39% to $19.4 million in 2024, then plummeted by 489.29% to -$75.5 million in 2025, then skyrocketed by 114.79% to $11.2 million in 2026.
  • The last three reported values for EBITDA were $11.2 million (Q1 2026), -$75.5 million (Q4 2025), and $17.8 million (Q3 2025) per Business Quant data.